

## News Release

### **Beat In-Albon new COO of the Life Science Ingredients Sector**

**Basel, Switzerland, 1 June 2012** – Starting on 1 June 2012, Beat In-Albon will join Lonza as COO of the Life Science Ingredients Sector and become a member of the Management Committee, replacing Harry Boot. Beat In-Albon brings broad industry experience to his role, having worked for Lonza already from 1983-2006, where he was Head of the Organic Fine & Performance Chemicals Division, and for SGS from 2006-2012, where he held different management positions.

As COO of Lonza's Life Science Ingredients Sector Beat In-Albon will focus primarily on the project "Visp Challenge", which is of significant importance to the expected profitability improvements in this sector. He will take full ownership of the project and will dedicate significant time and efforts to make it a sustainable success.

"I'm really happy to have Beat In-Albon back with Lonza. He brings on the one hand in-depth knowledge of the LSI business and the Visp site, and on the other hand valuable outside views," comments Richard Ridinger, CEO of Lonza. "With this new assignment, Lonza will further strengthen the focus on the Visp Challenge project."

Beat In-Albon is sixty years old and holds a Ph.D. degree in economics from the University of Fribourg.

Harry Boot will step down from the Management Committee and concentrate on his activities in Asia, especially in China.

#### **About Lonza**

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

## News Release

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.69 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

### Additional Information

Lonza Group Ltd  
Head of Corporate Communications  
Dominik Werner  
Tel +41 61 316 8798  
Fax +41 61 316 9798  
[dominik.werner@lonza.com](mailto:dominik.werner@lonza.com)

Lonza Group Ltd  
Investor Relations  
Dirk Oehlers  
Tel +41 61 316 8540  
Fax +41 61 316 9540  
[dirk.oehlers@lonza.com](mailto:dirk.oehlers@lonza.com)

Lonza Group Ltd  
Media Relations  
Melanie Disa  
Tel +1 201 316 9413  
Fax +1 201 696 3533  
[melanie.disa@lonza.com](mailto:melanie.disa@lonza.com)